Lisata Therapeutics, Inc. (LSTA) is a biopharmaceutical firm focused on developing innovative treatments that significantly improve the outcomes of serious diseases. The company aims to create a new paradigm of patient care with precise, individualized therapies utilizing the latest advancements in genetic and molecular medicine.
Based in the United States, LSTA is committed to advancing therapeutic areas by applying a unique, patient-centric approach. This involves bridging the gap between molecular biology knowledge and clinical applications, in order to bring novel, transformational therapies to patients who need them.
The company's comprehensive portfolio spans programs in areas of considerable unmet medical need, such as cancer, cardiovascular diseases, and other serious conditions. LSTA works on harnessing the body's innate capabilities to fight diseases, with the potential to dramatically change patients' lives by offering treatments that previously seemed inconceivable.
LSTA marks a compelling blend of talented scientists, experienced management, and cutting-edge technology. These resources, coupled with a strong focus on translational science and clinical development, allow the company to effectively translate groundbreaking scientific discoveries into proven medical treatments.
Central to LSTA's scientific ethos is an unwavering commitment to rigorous R&D. By investigating the fundamental processes driving disease pathogenesis, the company aspires to discover breakthrough therapies that can transform disease understanding and treatment protocols.
Of equal importance to the company's innovation-focused approach is its commitment to ethical conduct. LSTA makes every effort to ensure its research and processes uphold the highest standards of integrity, transparency, and patient wellbeing. Above all, the company prioritizes the health and well-being of the patients relying on its products.
LSTA is driven by the fundamental belief that every patient deserves a unique, targeted therapy that maximizes their chances of conquering their disease. In addition to its own robust drug pipeline, LSTA actively seeks out partnerships and collaborations that will accelerate the development and delivery of these promising therapies. By doing so, it strives to achieve its mission of transforming lives through the power of precision, targeted healthcare.
While still relatively early in its development journey, LSTA is well-positioned to make significant strides within the pharmaceutical industry. With a scientific foundation built on genomics and molecular biology and a corresponding focus on capitalizing on the latest advancements in these fields, Lisata Therapeutics, Inc. is at the cutting edge of medical innovation. As the company continues to grow and evolve, it remains steadfastly focused on its fundamental goal: creating transformative therapies that significantly improve patient outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This small cap wrap highlights several companies, including Nextech3D.ai which surpassed $1 million in new customer contract value for the year, and Nine Mile Metals which reported high-grade copper-equivalent intercepts at its Wedge Mine. Lisata Therapeutics' subsidiary Marea Therapeutics announced data presentation for its lead candidate MAR001 at a major medical conference, while Silver Range Resources identified new drill targets at its Drum gold project. The article also covers Rainbow Rare Earths' partnership with Neo Performance Materials, Scancell Holdings securing significant debt financing, Solis Minerals commencing drilling at a lithium project, and AuMEGA Metals completing its first diamond drilling program.
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc., will present data from its Phase 2b TYDAL study for MAR001 at the American Heart Association Scientific Sessions 2026. MAR001 is an experimental antibody targeting the ANGPTL4 protein to lower triglycerides and improve fat metabolism, a promising approach for conditions like severe hypertriglyceridemia. The presentation is scheduled for Monday, November 9, at 8:00 a.m. CT.
Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225 million in financing, which is projected to fund operations through 2028 and support key clinical trials. However, this deal results in substantial dilution for existing shareholders, who will retain only about 2.39% ownership. The success of this move hinges on the acquired pipeline's ability to generate significant value, as well as the management of potential cash settlement obligations related to preferred shares.
Lisata Therapeutics has acquired Marea Therapeutics and secured $225 million in financing to advance clinical-stage drug candidates for cardioendocrine diseases. Concurrently, mAbxience and Sandoz have partnered to develop and commercialize an emicizumab biosimilar for hemophilia A, targeting a global market valued at approximately $5.7 billion. These deals aim to push late-stage programs and broaden patient access to biologic medicines.